109
Participants
Start Date
October 7, 2019
Primary Completion Date
April 29, 2025
Study Completion Date
April 29, 2025
Within-Subject test of blinded study medication
On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
Johns Hopkins School of Medicine, Baltimore
National Institute on Drug Abuse (NIDA)
NIH
Johns Hopkins University
OTHER